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Key Clinical Message
We report on a male patient with severe autistic disorder, lack of oral language,
and dysmorphic features who carries a rare interstitial microdeletion of
4.96 Mb at chromosome 6q14.1-q15. The patient also harbors a maternally
inherited copy number gain of 1.69 Mb at chromosome Xp22.31, whose patho-
genicity is under debate.
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Introduction
In recent years, the use of Comparative Genomic Hybrid-
ization (CGH) and Single Nucleotide Polymorphism
(SNP) arrays as the first genetic test for the diagnosis of
neurodevelopmental disorders is enabling a genome-wide
approach and the identification of new submicroscopic
chromosomal abnormalities (namely Copy Number Vari-
ants or CNVs), undetectable by conventional techniques.
Here, the molecular analysis using a high-resolution SNP
array has allowed the identification of a rare heterozygous
deletion of 4.96 Mb at 6q14.1-q15 and affecting 31 genes
in a male patient with severe autistic disorder (AD), lack of
oral language, and dysmorphic features. Interstitial
deletions within the proximal region of the long arm of
chromosome 6 are rare, variable in size, and location,
involve different genes, have been implicated in develop-
mental delay (DD), behavioral problems, autism (A), early-
onset obesity, characteristic facial dysmorphism, and
syndactyly of toes II/III, and are mainly de novo [1–5].
Coexisting in our patient, a subtelomeric maternally inher-
ited copy-number gain of 1.69 Mb at Xp22.31 and encom-
passing six genes was also detected. Copy number gains at
Xp22.31 are variable in size, location, and gene content,
and they have been detected in patients with DD, intellec-
tual disability (ID), A, seizures, dysmorphism, and/or mul-
tiple congenital anomalies (MCA). But since they have also
been identified in healthy carrier parents and in controls, it
has been proposed that these duplications are benign [6].
However, its potential pathogenicity is still under debate
[7–15]. A plausible explanation for the incomplete
penetrance and the phenotypic heterogeneity of these
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chromosomal aberrations could be the coexistence of addi-
tional CNVs that might contribute to the patient’s pheno-
types [11]. So, a multiple-hit hypothesis, first proposed by
Girirajan et al. [16] for the 16p12.1 microdeletions, could
occur in our patient who, in addition to the Xp22.31 copy
number gain, presents the 6q14.1-q15 microdeletion.
Here, we perform the clinical description and the
molecular characterization of a male patient with a
6q14.1-q15 microdeletion. Furthermore, we review the
previously reported patients with chromosomal CNVs in
this region searching for plausible candidate genes. Alter-
natively, and taking into account that the pathogenicity
of the Xp22.31 duplication is still unclear, the two-hit
model is also discussed.
Materials and Methods
DNA samples from both the patient and his mother
were obtained from peripheral blood and genotyped
with the Affymetrix CytoScan High-Density SNP array
and the Affymetrix CytoScan 750K SNP array (Affyme-
trix, Santa Clara, CA), respectively. The father’s sample
was not available for genetic analysis. Microarray-based
copy number analysis was performed using the Chromo-
some Analysis Suite software version 1.2.2 (Affymetrix)
and the results were presented on the human genome
assembly hg19 (Figs. 1 and 2).
Results
Clinical report
Our patient, an 8-year-old male, is the first child of a non-
consanguineous couple of European descent. His family
history is unremarkable, with the exception that his mother
presented degenerative otosclerosis and required surgery
on her right ear. The pregnancy was uneventful without
remarkable prenatal data. Delivery was by cesarean section
due to dystocia. Apgar scores were 8–10 at 1–5 min, respec-
tively. His birth weight was 3080 g. Neonatal metabolic
screening was normal. He presented scoliosis and mild
hypospadias (surgery not required).
A neuropediatric clinical evaluation was performed at
2 years and 9 months. Weight: 12 kg (3rd–10th centile),
height: 87.5 cm (3rd centile), head circumference: 49 cm
(25th centile). Physical examination also showed a
squared craniofacial profile, a wide forehead, sparse eye-
brows in the outer portion, antimongoloid palpebral
slant, a long, and prominent philtrum, micrognathia, a
depressed nasal bridge, a thin upper lip, and large ears.
Figure 1. Microarray-based copy number analysis performed with the Affymetrix CytoScan High-Density array (patient) and the Affymetrix
CytoScan 750K array (his mother) and visualized using the Affymetrix Chromosome Analysis Suite version 1.2.2. Image of the 4.96 Mb deletion
at 6q14.1-q15 (chromosome 6: 83,648,997–88,613,065 bp; hg19) present in the patient (A) and absent in his mother (B). The father’s DNA was
not available for genetic analysis.
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Clinodactyly of both fifth fingers. No pigmentary abnor-
malities were observed. Normal results were obtained in
the following tests: Audiometry and auditory evoked
potentials, brain Magnetic Resonance Imaging (MRI),
dorsal/lumbar spine MRI (unless a doubtful segmentation
in D10 which has been attributed to his scoliosis), and
renal ultrasound. At the behavioral level, no sleeping or
eating difficulties were noted. He presented enuresis and
encopresis that remain to date.
At 3 years and 9 months, an extensive clinical interview
was performed and he was diagnosed with pervasive
developmental disorder, specifically AD, according to the
Diagnostic, and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR). In addition,
the Childhood Autism Rating Scale (CARS [17]) was
applied, achieving a score of 39, which placed him in the
category of severe autism.
At 8 years, the patient underwent a comprehensive aut-
ism-focused diagnostic assessment. Results from the Autism
Diagnostic Interview – Revised (ADI-R) were consistent
with AD: Qualitative Abnormalities in Reciprocal Social
Interaction (total score 27; cutoff = 10); Qualitative Abnor-
malities in Communication (total score 14; cutoff = 8);
Restricted, Repetitive and Stereotyped Patterns of Behavior
(total score 10; cutoff = 3); Abnormality of Development
Evident at or before 36 months (total score 4; cutoff = 1).
At the same age, the Child Behavior Checklist (CBCL
[18]) was administered. Results pointed to two main
areas of clinical concern: lack of communication and
hyperactivity. Finally, it was no possible to proceed with
the neuropsychological assessment, since the patient
refused to cooperate and showed no interest in the inter-
action with the evaluator. Nevertheless, clinical judgment
led to conclude that his cognitive abilities and adaptive
behavior were compatible with the diagnostic of severe
intellectual disability.
From data collected at the above-mentioned different
points of assessment, we can remark some patient’s clini-
cal and developmental characteristics. Early signs of devel-
opmental delay appeared around 4–6 months old because
of hypotonia and both fine and gross motor deficits. He
reached unsupported sitting before the first year and
independent walking at 22 months.
The development of the prelinguistic communication
showed an evident delay. At 1 year and 6 months, his use
of gestures was limited to imitation and the use of the
“goodbye”, although external elicitation was always neces-
sary. The lack of pointing gesture was particularly evident,
both in the protoimperative and protodeclarative forms.
To date, he continues without being able to point and
barely understands the meaning of this gesture in others.
The development of nonverbal communication strategies
Figure 2. Microarray-based copy number analysis performed with the Affymetrix CytoScan High-Density array (patient) and the Affymetrix
CytoScan 750K array (his mother) and visualized using the Affymetrix Chromosome Analysis Suite version 1.2.2. Image of the 1.69 Mb gain at
Xp22.31 (chromosome X: 6,446,579–8,135,644 bp; hg19) present in both the patient (A) and his mother (B).
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remained without improvement. Around 3 years, he did
not use gestures or basic facial expressions and only very
occasionally responded to his own name. He is still
described as a very inexpressive child (except for the fact
that frowns when he is angry). However, he uses some
body gestures (mostly stereotypes) to help the expression
of emotional states. Eye contact, although brief, is
presumed to have improved from previous stages. Never-
theless, he avoids eye contact except with his mother.
Regarding language development, his first words
occurred when he was 1-year-old. He began producing
only a couple of words with referential meaning, but he
did not show progress over the time. At 3 years, an evi-
dent verbal regression was observed, until a complete
absence of expressive language. To date, he continues
being nonverbal, with a very limited language understand-
ing. In the last year, alternative/augmentative communica-
tion systems were introduced.
At the social area, he was a baby who did not show a
clear interest neither in things from his near environment
nor in interactive and circular games with social agents.
He did not show use of attachment objects. As a remark-
able social behavior, he only developed the social smile, a
characteristic still present to date.
At the beginning of preschool age, he rejected to hold
interactions with his peers. However, at the primary
school years he started to show some interest in other
children, although he still prefers to be with adults. His
games are very simple and little structured. From primary
education, he has required special educational support,
both at and outside school.
In relation to behavior, he displays a clear hyperactive
profile. He presents special difficulties with focused and
sustained attention. He tends to show repetitive behaviors
and several motor stereotypes (such as turn on and turn
off lights, open and close doors, jumps, hand flapping,
claps, bizarre “goodbye” gestures, etc.). When he is very
angry or under stress, he grabs his head with the hands
and rubs or leans himself against a wall.
In the present patient, besides a diagnosis of AD, symp-
toms, and signs obtained through his clinical interview and
psychopathological examination suggest a comorbid
diagnosis of attention deficit and hyperactivity disorder
(ADHD) and intellectual disability.
Craniofacial features at the age of 8 years are shown in
Figure 3.
Molecular analysis
Microarray-based copy number analysis, performed with the
CytoScan High-Density SNP array (Affymetrix), allowed the
detection of two rare exonic CNVs in our patient: a hetero-
zygous 4.96 Mb loss at 6q14.1-q15 (chromosome 6:
83,648,997–88,613,065 bp; hg19) including 31 genes
(UBE2CBP, DOPEY1, PGM3, RWDD2A, ME1, PRSS35,
SNAP91, RIPPLY2, CYB5R4, MRAP2, KIAA1009, TBX18,
NT5E, SNX14, SYNCRIP, SNHG5, SNORD50A, SNORD50B,
HTR1E, CGA, ZNF292, GJB7, C6orf162, C6orf163, C6orf164,
C6orf165, SLC35A1, RARS2, ORC3, AKIRIN2, and
NCRNA00120) (Fig. 1A) and a 1.69 Mb copy number gain
at Xp22.31 (chromosome X: 6,446,579–8,135,644 bp; hg19)
encompassing six genes (VCX3A, HDHD1, STS, VCX,
PNPLA4, and MIR651) (Fig. 2A). A total of 4124 and 4408
markers with a median intermarker distance of 1.2 and
0.4 kb, respectively, cover the 6q14.1-q15 and Xp22.31 inter-
vals, respectively. The genetic analysis of the patient’s
mother, performed with the Affymetrix CytoScan 750K SNP
array, verified that she carries the Xp22.31 gain (Fig. 2B) but
(A) (B)
Figure 3. Craniofacial appearance of the patient at the age of 8 years. Note a squared craniofacial profile, a wide forehead, sparse eyebrows in
the outer portion, antimongoloid palpebral slant, a long and prominent philtrum, micrognathia, and large ears.
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not the 6q14.1-q15 microdeletion (Fig. 1B). The father’s
sample was not available for genetic analysis.
Discussion
The use of high-resolution chromosomal microarrays for
CNV detection is favoring the identification of submicro-
scopic chromosomal abnormalities, undetectable by
conventional cytogenetic techniques and with an
approach that allows to study the whole genome in a sin-
gle test [19–21]. Consequently, their application in the
clinical setting has increased the diagnostic yield in the
genetic evaluation of patients with neurodevelopmental
and psychiatric disorders [22, 23]. However, the interpre-
tation of the genetic findings is not always straightforward
[24], being hampered by the detection of benign variants
and/or variants of uncertain significance and/or by the
coexistence of multiple genetic variants within a single
genome. These two possibilities occur in our patient who,
in addition to a deletion in the long arm of chromosome
6 (Fig. 1), has a maternally inherited variant of unclear
significance at Xq22.31 (Fig. 2).
Figure 4 shows the submicroscopic interstitial deletions
at 6q13-q16.1 reported in the literature with total or par-
tial overlapping with the 6q14.1-q15 deletion identified in
our patient. These alterations have been detected by
molecular cytogenetic techniques in patients with hetero-
geneous phenotypes, are rare variants, differ in size, and
location, and encompass different genes [1–6] (Fig. 4),
making the delineation of genotype-phenotype correla-
tions a challenging task. However, Wentzel et al. [5]
reported two patients with deletions at chromosome
6q14.1-q15, one of them almost identical in size, location,
and gene content to that of our patient (Fig. 4A–B).
These two reported patients have a common phenotype
characterized by DD, motor delay, early-onset obesity,
hernia, characteristic facial dysmorphism (rounded face
with full cheeks, epicanthal folds, short palpebral fissures,
bulbous nose, large ears), and syndactyly between toes II
and III [5], features all shared by a previously published
patient with an overlapping deletion in this region [25].
Additional features of patient 1 described by Wentzel et al.
[5] include small and obese hands and feet, with fragile
nails and ophthalmological, hearing and renal abnormali-
ties as well as attention deficit and aggressive behavior. His
patient 2 also presented additional clinical manifestations,
including ophthalmologic abnormalities, mild pectus
excavatum, early scoliosis improved with age, inverted
nipples, a cafe-au-lait patch on the right side of his chest,
ECG anomalies (mild right ventricular conduction delay)
Figure 4. Schematic overview of the 6q14.1-q15 region showing the RefSeq and OMIM-morbidity genes and SNP array results in our patient and
in previous reports with interstitial submicroscopic 6q14.1-q15 deletions identified by molecular techniques [1–5]. The UCSC Genome LiftOver
Tool was used for converting genome coordinates between hg18 and hg19 assemblies, where necessary. Longer interstitial 6q deletions described
in the literature and detected by conventional cytogenetics are not included in this scheme [reviewed by Refs. 42, 43].
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and, regarding his behavior, he was hyperactive and had
anomalous seeking food behaviors [5]. Our patient has a
deletion similar in size and location to that of this patient
2, which is almost entirely included into patient 1’s dele-
tion (Fig. 4A–B) [5]; however, despite the similarities in
their genotypes, not only phenotypic resemblances but also
significant differences between these patients were noted.
The features shared by the above-mentioned patients and
the one presented here include: DD, motor delay, hypoto-
nia, digital abnormalities, and some (i.e., large ears;
bulbous nose) but not all the facial dysmorphic character-
istics. Our patient, however, does not have early-onset
obesity (strikingly, he is thin rather than obese) or hernia
or any of the congenital abnormalities reported by Wentzel
et al. [5], such as cardiac, ophthalmologic, hearing, renal,
or skeletal defects, with the sole exception of scoliosis.
Finally, all these three patients have behavior problems,
although some differences in this regard are also striking:
attention deficit and aggressive behavior in patient 1,
hyperactivity and obsessive seeking food behaviors in
patient 2 [5] and AD and ADHD (but not aggressiveness
or feeding problems) in our patient. It seems that intersti-
tial deletions at 6q14.1-q15 might be associated with very
different phenotypes, as it has been previously suggested
by Lowry et al. [2]. These authors found that his patient,
despite having a very similar deletion to patient 1
described by Wentzel et al. [5], only shared some features
(DD, hypotonia, and anomalous feeding behavior), but
had a completely different facial dysmorphism and, as our
patient, was thin rather than obese [2]. Recently, Pinto
et al. [3] described a male patient with A, severe ID,
absence of language, one seizure event in his life, macro-
cephaly, long and narrow hands and feet and 2 cafe-au-lait
spots and a de novo 23 kb 6q14.3 microdeletion encom-
passing two genes, SYNCRIP and SNX14, both deleted in
our patient (Fig. 4D). Becker et al. [1] have also reported
two patients with 6q chromosomal alterations, one with a
de novo deletion of 8.9 Mb in the 6q14.1-q14.3 region
partially overlapping with that of our patient. His pheno-
type was characterized by neonatal jaundice, DD, cardiac
malformations, and dysmorphic features (Fig. 2E). Finally,
one of the four patients described by Van Esch et al. [4]
with 6q13-q14 deletions has a de novo 25 Mb deletion,
which includes our patient’s CNV. The phenotype was
characterized by DD, mild dysmorphism, umbilical hernia,
hypotonia, small kidneys and skeletal, ophthalmologic and
hearing abnormalities, as well as recurrent respiratory
infections (Fig. 4F). It seems, therefore, that interstitial
deletions at the proximal 6q region are associated with het-
erogeneous phenotypes and these differences might be due
to multiple reasons: (1) For those deletions more similar
in size, location, and gene content, such as the one in our
patient and in patients described by Wentzel et al. [5] and
Lowry et al. [2] (Fig. 4A–C), one could speculate with the
existence of recessive mutations in the nondeleted allele
and/or the presence of additional modifying factors else-
where in the genome, as could be the case of the Xp22.31
gain in our patient and the 1p31.1 duplication in patient 2
reported by Wentzel et al. [5], as well as environmental
and/or epigenetic modifiers. (2) In the case of the other
aforementioned CNVs [1, 3, 4] (Fig. 4D–F), difference in
size, location, breakpoints and, in consequence, gene con-
tent might account for this phenotypic heterogeneity.
The 6q region deleted in our patient encompasses 31
genes in total, including SLC35A1 (Solute carrier family
35 (CMP-sialic acid transporter), member 1; Online Men-
delian Inheritance in Man (OMIM) 605634) and RARS2
(Arginyl-tRNA synthetase 2; OMIM 611524) as morbidity
genes listed in the OMIM database and are cause of con-
genital disorder of glycosylation type IIf (OMIM 603585)
and pontocerebellar hypoplasia type 6 (OMIM 611523),
respectively. Candidate genes for our patient’s phenotype
can potentially include: PGM3 (phosphoglucomutase 3),
PRSS35 (protease, serine, 35), SNAP91 (synaptosomal-
associated protein, 91kDa), RIPPLY2 (ripply transcrip-
tional repressor 2), MRAP2 (melanocortin 2 receptor
accessory protein 2), SYNCRIP (synaptotagmin binding,
cytoplasmic RNA interacting protein), SNX14 (sorting
nexin 14), and HTR1E (5-hydroxytryptamine (serotonin)
receptor 1E, G protein-coupled). Thus, Zhang et al. [26]
have recently detected, in two unrelated families, recessive
mutations in the gene PGM3 that segregate with a pheno-
type characterized by severe atopy, immune deficiency,
autoimmunity, hypomyelination, and ID. A genome-wide
association study has suggested an association between
psychotic features (mood-incongruent psychotic features)
of bipolar disorder and common polymorphisms in sev-
eral genes expressed in the nervous system, including a
SNP located at 6q14.2 within the gene complex PRSS35-
SNAP91, although did not reach statistical significance
[27]. It has also been suggested that PRSS35 could be
involved in craniofacial abnormalities, particularly in cleft
lip/palate [28]. Also interestingly, McInerney-Leo et al.
[29] have recently indentified compound heterozygous
mutations in RIPPLY2 segregating in a family with verte-
bral segmentation defects, further supporting previous
evidence for a role in somite segmentation and the estab-
lishment of rostrocaudal patterning of somites during
mouse early development [30–32] and providing a plausi-
ble candidate gene for the skeletal defects seen in patients
with 6q14.1-q15 deletions, as the one reported here.
Although, as previously mentioned, patient described by
Lowry et al. [2] and our patient are thin rather than
obese, early-onset obesity has been reported in several
patients with deletions at 6q14.1-q15 [5]. One of the
genes included in these deletions, MRAP2, has been
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linked to obesity in mammals and zebrafish [33–35], so
one could hypothesize that this gene might also be
involved in the obesity seen in these patients, for example,
unmasking recessive loss-of-function mutations in the
nondeleted allele. Although additional evidence is needed
to definitively consider SYNCRIP causal for neurodevel-
opmental disorders, it is important to note that a de novo
loss-of function mutation has been reported in this gene
in a patient with severe nonsyndromic ID [36] and, as
previously discussed, Pinto et al. [3] have recently found
a de novo microdeletion affecting SYNCRIP and SNX14
in a patient with a phenotype mainly characterized by A,
severe ID, and absence of language, similar to our patient.
Finally, several genetic approaches (linkage, family-based,
candidate gene, and genome-wide association studies)
have suggested a potential role for HTR1E in ADHD [37–
39] and suicidal behavior [40] and epigenetic studies have
provided evidence of differential methylation of the pro-
moter of HTR1E in patients with first-episode schizophre-
nia versus controls [41].
Duplications at the subtelomeric Xq22.31 region, where
deletions or mutations affecting the STS gene (Steroid
Sulfatase; OMIM 300747) are involved in X-linked ichthy-
osis (OMIM 308100), vary in size, location, and gene
content, and have been considered as either a cause or
risk factor for DD/ID or a benign variant, still existing a
controversy regarding its clinical significance [6–15].
Thus, Li et al. [10] identified 29 individuals of a total of
7993 patients (0.37%) with DD, DI, A, dysmorphism,
and/or MCA with subtelomeric Xp22.31 copy number
gains ranging in size between 149 kb and 1.74 Mb. Nev-
ertheless, they also found Xp22.31 alterations in control
population and although the frequency was lower
(0.15%), their findings questioned the pathogenicity of
these CNVs. Subsequently and in larger series of samples,
Liu et al. [11] also studied and compared the frequencies
of the Xp22.31 copy number gains between patients
(n = 20,095) and controls (n = 5088) and no statistically
significant differences were found, neither in the overall
prevalence nor when the data were analyzed by gender.
Furthermore, they found that these alterations were
mostly inherited from a healthy parent, further complicat-
ing the clinical interpretation. Finally, Furrow et al. [6]
argued that these duplications were benign; they detected
duplications of the STS region in 72 male patients and
segregation analysis in 40 of them revealed that each
patient had inherited the CNV from a phenotypically
normal mother. Furthermore, 10 of the 72 patients (14%)
had an additional CNV that was believed to be causative
of their phenotypes. Nevertheless, Faletra et al. [9] found
that no Xp22.31 duplications were detected in a total of
2055 control individuals and concluded that this finding,
along with the description of a new patient with a de
novo Xp22.31 duplication, would support the pathogenic-
ity of this CNV leading to a phenotype of ID and minor
facial dysmorphism without major anomalies. Recently,
Esplin et al. [8] described nine patients with duplications
of Xp22.31 that seem to contribute to a common pheno-
type mainly characterized by DD, talipes abnormalities,
seizures, feeding difficulties, and a variable facial dysmor-
phism. Concerning the phenotype, Liu et al. [11]
obtained detailed clinical information of 14 of their
patients, who mainly presented DD and behavioral and
social interaction problems, including stereotypic features
such as hand flapping and avoidance of eye contact, fea-
tures all presented in our patient.
There are different plausible explanations for the
incomplete penetrance and the phenotypic heterogeneity
of these X-CNVs, including the following: (1) Difference
in size, location and genomic content of the copy number
gains [8, 10, 11]. (2) Difference in their population fre-
quencies, as it has been suggested by Li et al. [10] and
Liu et al. [11]. (3) Unnoticed phenotype in controls and/
or carrier parents if it is presented as a milder or subclini-
cal phenotype [11] or if improves with age. (4) Skewed
X-inactivation, although discrepancies between authors
have been reported [10, 11]. (5) That the Xp22.31 copy
number gain is not the cause but a risk factor that trig-
gers the phenotype if additional factors are present. These
modifiers could be environmental, genetic (supporting
the multiple-hit hypothesis) and/or epigenetic factors. In
this regard, Liu et al. [11] found that at least 17.2% of
the patients with the recurrent duplication carried addi-
tional CNVs in their genomes and suggested that these
could contribute to their phenotypic manifestations. This
is also the case of our patient who, in addition to the
maternally inherited Xp22.31 gain of unclear clinical sig-
nificance, carries the above-mentioned 6q14.1-q15 mic-
rodeletion.
The breakpoints of the Xp22.31 copy number gain in our
patient are flanked by segmental duplications (Fig. 2) so, as
it has been proposed [11], nonallelic homologous recombi-
nation (NAHR) is likely the underlying mechanism.
In conclusion, we have described here a patient who
harbors a 6q14.1-q15 microdeletion and presents severe
AD, lack of oral language and dysmorphic features. The
use of genome-wide high-resolution SNP arrays for copy
number analysis has been proven to be an extremely valu-
able approach in the identification of genetic causes of
neurodevelopmental disorders. However, discrimination
between benign and pathogenic variants and the establish-
ment of genotype-phenotype correlations are not always
straightforward tasks. Thus, our report may represent an
example to illustrate the difficulty in interpreting genetic
data, especially when these variants present phenotypic
heterogeneity and/or incomplete penetrance and/or when
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multiple variants, associated with overlapping pheno-
types, coexist in a single genome. In addition, we
emphasize the need to report detailed clinical descrip-
tions to facilitate this interpretation and to aid to pro-
vide appropriate family genetic counseling and patient
management.
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